Clinical efficacy and patient satisfaction with U-500 insulin use

Diabetes Research and Clinical Practice

Volumn 88, Issue 3, 2010, Pages 259-264

  Dailey, Alexandria M ^a   Williams, Sarah ^a   Taneja, Deepa ^a   Tannock, Lisa R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

HbA1c; Hypoglycemia; Insulin resistance; Weight gain

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; ISOPHANE INSULIN; PIG INSULIN; U 500 INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DIABETES CONTROL; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN HYPOGLYCEMIA; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; WEIGHT GAIN; BLOOD; HYPOGLYCEMIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 78349231705     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.02.012     Document Type: Article

References (17)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, The Diabetes Control and Complications Trial Research Group, N. Engl. J. Med. (1993) (329) 977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), UK Prospective Diabetes Study (UKPDS) Group, Lancet (1998) (352) 837-853.
3. Garg R., Johnston V., McNally P.G., Davies M.J., Lawrence I.G. U-500 insulin: why, when and how to use in clinical practice. Diab. Metab. Res. Rev. 2007, 23:265-268.
4. Galloway J.A., Spradlin C.T., Nelson R.L., Wentworth S.M., Davidson J.A., Swarner J.L. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981, 4:366-376.
5. Lane W.S., Cochran E.K., Jackson J.A., Scism-Bacon J.L., Corey I.B., Hirsch I.B., et al. High-dose insulin therapy: is it time for U-500 insulin?. Endocr. Pract. 2009, 15:71-79.
6. Ballani P., Tran M.T., Navar M.D., Davidson M.B. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care 2006, 29:2504-2505.
7. Bulchandani D.G., Konrady T., Hamburg M.S. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr. Pract. 2007, 13:721-725.
8. Knee T.S., Seidensticker D.F., Walton J.L., Solberg L.M., Lasseter D.H. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr. Pract. 2003, 9:181-186.
9. Lane W.S. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr. Pract. 2006, 12:251-256.
10. Neal J.M. Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocr. Pract. 2005, 11:305-307.
11. Wafa W.S., Khan M.I. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care 2006, 29:2175-2176.
12. Burroughs T.E., Desikan R., Waterman B.M., Gilin D., McGill J. Development and Validation of the Diabetes Quality of Life Brief Clinical Inventory. Diabetes Spectr. 2004, 17:41-49.
13. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial, Am. J. Cardiol. (1995) (75) 894-903.
14. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359:1577-1589.
15. Weight gain associated with intensive therapy in the diabetes control and complications trial, The DCCT Research Group, Diabetes Care (1988) (11) 567-573.
16. Crasto W., Jarvis J., Hackett E., Nayyar V., McNally P.G., Davies M.J., et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad. Med. J. 2009, 85:219-222.
17. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol. Toxicol. (Copenh) 1969, 27(Suppl. 2):1-84.